SMAD3 and breast carcinoma: Next, the binding sites of STAT3 in the KRAS or TGF-β promotor regions were predicted using rVista 2.0 software according to the JASPAR [26] and are shown in Fig. 3D. In addition, analysis of STAT3-related genes using the GEPIA database revealed that the levels of STAT3 expression were correlated positively with that of KRAS, NRAS, and MRAS (Fig. S3A), as well as with TGFB2, SMAD2, and SMAD3 (Fig. S3B) in breast cancers.